Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Caplin Point Laboratories Ltd
EPS (Diluted)
Caplin Point Laboratories Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
EPS (Diluted)
₹67
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
32%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
EPS (Diluted)
₹64
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
EPS (Diluted)
₹61
|
CAGR 3-Years
25%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
EPS (Diluted)
₹47
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
EPS (Diluted)
₹55
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
EPS (Diluted)
₹47
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Caplin Point Laboratories Ltd
Glance View
Nestled in the bustling business corridors of Chennai, Caplin Point Laboratories Ltd. emerged quietly yet resolutely from its humble origins in 1990. With foresight and strategic maneuvering, the company embarked on a global journey, primarily serving markets across the African, Latin American, and Southeast Asian regions. The firm specializes in a wide array of pharmaceutical products, encompassing everything from injectables and ophthalmics to oral solids and liquids. By focusing on markets that were often overlooked by larger pharmaceutical giants, Caplin Point carved out a niche that allowed it to flourish with minimal competition. The company's business model hinges on leveraging cost-effective manufacturing paired with a deep understanding of diverse regulatory environments, deftly navigating these to establish a loyal customer base amidst underrepresented geographies. The revenue streams of Caplin Point Laboratories are primarily fueled by its ability to adapt product lines to meet the specific needs of each market it serves. This adaptability, combined with a robust distribution network, facilitates the swift movement of goods—ensuring prompt delivery to consumers who rely on its products for basic health needs. Through strategic partnerships and continual investment in research and development, Caplin Point enhances its capacity for innovation, allowing it to advance the quality and range of its pharmaceutical offerings. Furthermore, the company has steadily expanded into regulated markets with its sights set on injectables and has plans for further diversification. This strategic orientation underscores its ambition to transition from a regional powerhouse to a formidable player on the broader global stage.
See Also
What is Caplin Point Laboratories Ltd's EPS (Diluted)?
EPS (Diluted)
67.5
INR
Based on the financial report for Dec 31, 2024, Caplin Point Laboratories Ltd's EPS (Diluted) amounts to 67.5 INR.
What is Caplin Point Laboratories Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
32%
Over the last year, the EPS (Diluted) growth was 17%. The average annual EPS (Diluted) growth rates for Caplin Point Laboratories Ltd have been 22% over the past three years , 19% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet